Gene Expression Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Process (Sample Collection, Purification, cDNA synthesis & conversion, PCR Analysis, Data analysis & interpretation), By Product (Kits & Reagents, DNA Chips, Others), By Capacity (Low- to Mid- Plex, High-Plex), By Application (Drug Discovery & Development, Clinical Diagnostics, Biotech & Microbiology, Others), By Technique (RNA Expression, Promoter Analysis, Protein Expression & Posttranslational Modification Analysis), By Region and Competition, 2020-2030F

Market Overview

The Global Gene Expression Market, valued at USD 15.78 Billion in 2024, is projected to experience a CAGR of 5.58% to reach USD 21.86 Billion by 2030. Gene expression delineates the fundamental cellular process whereby genetic information from DNA is converted into functional gene products, primarily proteins or RNA molecules, thereby dictating specific cellular attributes and functions. The market's expansion is significantly propelled by continuous advancements in genomic research and sequencing technologies, the escalating global incidence of chronic and infectious diseases necessitating precise diagnostic and prognostic tools, and growing investments in biopharmaceutical research and development for novel therapeutic discovery.

Despite these positive drivers, a notable impediment to market growth is the substantial capital outlay required for implementing and maintaining advanced gene expression analysis platforms, including high-throughput sequencing technologies and complex bioinformatics infrastructure. This financial barrier can restrict broader adoption, particularly among smaller research entities. According to the Biotechnology Innovation Organization, in 2022, the biotechnology health sector was responsible for the development of over 250 vaccines and medications, exemplifying the industry's productive output which heavily relies on gene expression technologies.

Key Market Drivers

The global gene expression market is significantly influenced by continued advancements in genomics and biotechnology, which serve as foundational catalysts for innovation. These developments encompass sophisticated sequencing technologies, refined gene editing tools such as CRISPR, and comprehensive omics approaches, all of which enhance the depth and efficiency of gene expression analysis. This continuous evolution in scientific capabilities enables researchers to explore complex biological systems with unprecedented resolution, driving the discovery of new therapeutic targets and diagnostic biomarkers. According to the National Human Genome Research Institute, in March 2023, funding policy emphasized support for genomic sciences and genomic medicine applications, particularly those focusing on technology development and computational biology, underscoring the ongoing investment in these critical areas.

Concurrently, the growing demand for personalized and precision medicine profoundly impacts the gene expression market. This paradigm shift in healthcare emphasizes tailoring medical treatments to individual patient characteristics, including genetic makeup, for optimal efficacy and reduced adverse effects. Gene expression profiling is indispensable for identifying specific molecular signatures of diseases, predicting patient response to therapies, and monitoring treatment outcomes. This enables the development of highly targeted interventions. According to the Personalized Medicine Coalition, in February 2024, personalized medicines accounted for over one-third of new U. S. Food and Drug Administration drug approvals in 2023, illustrating the expanding clinical integration of these approaches. This trend highlights the critical role of gene expression insights in advancing individualized patient care. Furthermore, supporting the broader life sciences ecosystem that underpins gene expression research, according to the Association of University Technology Managers, in 2023, total research expenditures at U. S. academic institutions reached $104 billion, marking the highest level in over 30 years and a 13% increase from 2022.

Download Free Sample Report

Key Market Challenges

A significant challenge impeding the growth of the Global Gene Expression Market is the substantial capital outlay required for advanced analysis platforms. Implementing high-throughput sequencing technologies and establishing complex bioinformatics infrastructure necessitates considerable upfront investment. This financial burden restricts broader adoption, particularly among smaller research entities, emerging biotechnology firms, and academic laboratories operating with limited budgets. Such high initial and ongoing maintenance costs can delay or prevent these organizations from acquiring essential equipment and developing the necessary expertise, thereby hindering the widespread application of gene expression technologies across various research and clinical domains.

The scale of investment needed for this field is considerable. According to Genome Canada, in 2023-24, a total of $105.5 million was invested in genomics research, highlighting the extensive financial resources required to engage in and advance this scientific area. This capital intensity ultimately limits market penetration, as not all potential users possess the necessary resources to engage with these advanced platforms.

Key Market Trends

The expansion of spatial transcriptomics significantly advances gene expression analysis by offering critical contextual information, enabling visualization of gene activity within its native tissue microenvironment. This capability is essential for unraveling intricate disease mechanisms, identifying precise therapeutic targets, and discovering biomarkers. Spatial transcriptomics provides insights into cellular heterogeneity and cell-to-cell interactions, fostering notable market growth. For instance, in June 2024, Moleculent AB secured USD 25.0 million in Series A financing to advance its spatial mapping of cell-cell communication. This development is supported by broader industry investment, with the European Federation of Pharmaceutical Industries and Associations reporting an estimated €50,000 million invested in research and development in Europe in 2023.

The integration of artificial intelligence into bioinformatics workflows transforms gene expression analysis through efficient processing and interpretation of extensive, complex genomic datasets. AI algorithms enhance the discovery of biological patterns, improve predictive modeling for drug development, and accelerate the identification of disease-associated molecular signatures. This trend addresses genomic data overload, allowing researchers to extract deeper insights and validate hypotheses rapidly. For example, in January 2024, NVIDIA announced partnerships to accelerate drug discovery and genomic research with generative AI, collaborating with Amgen’s deCode to power new genomics foundation models using NVIDIA's BioNeMo platform. The U. S. National Science Foundation, in September 2024, encouraged proposals advancing biological research through artificial intelligence and machine learning methods, underscoring AI’s critical role.

Segmental Insights

The Kits & Reagents segment is a key driver within the Global Gene Expression Market, demonstrating rapid growth due to its indispensable role in various research and diagnostic applications. This expansion is primarily propelled by increasing global investments in life science research and development, particularly in genomics, proteomics, and drug discovery, which require a consistent supply of specialized consumables. Furthermore, technological advancements in gene expression analysis, such as next-generation sequencing and quantitative PCR, necessitate the continuous development and adoption of innovative and highly specific kits and reagents for accurate and efficient experimental execution. The ongoing introduction of advanced products designed for precise applications and the growing demand for personalized medicine further accelerate this segment's market progression.

Regional Insights

North America leads the global gene expression market, primarily driven by its advanced technological infrastructure and substantial investments in research and development. The region benefits from a robust biotechnology and biopharmaceutical sector, supported by a thriving ecosystem of academic institutions and research organizations. A favorable regulatory environment, exemplified by bodies such as the Food and Drug Administration, coupled with strong academia-industry partnerships, further fosters innovation. Additionally, the widespread adoption of precision medicine approaches and a well-established healthcare infrastructure contribute significantly to North America's market dominance.

Recent Developments

• In October 2025, ImmunoVec emerged from stealth operations, securing an award of up to $40.7 million from the Advanced Research Projects Agency for Health (ARPA-H) EMBODY program. The biotechnology company is pioneering an in vivo cell engineering platform for autoimmune diseases. This funding will expedite the development of its cell therapy, from preclinical stages through its first-in-human clinical trial. ImmunoVec's platform aims to restore normal gene expression, with preclinical data suggesting the potential to safely and effectively mitigate symptoms of serious immune diseases. This initiative signifies an advancement in gene and cell therapy delivery, offering a potentially more efficient and cost-effective approach.

• In February 2025, Roche unveiled its proprietary Sequencing by Expansion (SBX) technology, introducing a new category of next-generation sequencing. This breakthrough technology, combining SBX chemistry with an innovative sensor module, delivers ultra-rapid, high-throughput sequencing. The system offers flexibility and scalability for diverse applications, significantly reducing the time required from sample to genome from days to hours. This advancement is poised to accelerate genomic research and enhance translational and clinical applications by providing detailed insights into gene functions and interactions, crucial for decoding complex diseases such cancer, immune disorders, and neurodegenerative conditions.

• In October 2024, Illumina, a global genomics company, formalized a significant collaboration with National Taiwan University Hospital through a Memorandum of Understanding. This partnership initiated a large-scale Whole Genome Sequencing (WGS) Project, intended to sequence over 10,000 individuals. The hospital will leverage Illumina's high-throughput NovaSeq X Plus sequencing platform, which offers accelerated sequencing speeds for comprehensive genomic analysis. This collaboration is set to deepen insights into genetic profiles and variations associated with specific diseases, ultimately enhancing diagnostic and treatment strategies for conditions such as cancer, neurological disorders, and rare genetic diseases in Taiwan.

• In January 2024, Thermo Fisher Scientific introduced its next-generation Invitrogen TaqMan Cells-to-CT Express Kit, designed to streamline gene expression analysis workflows. This new product provides simplified and scalable processes for preparing cell lysates for reverse transcription real-time PCR (RT-qPCR) in just five minutes. The kit eliminates the traditional RNA purification step, allowing researchers to proceed directly from cultured cells to RT-qPCR. This innovation not only accelerates the workflow, delivering results from a plate of cells in approximately 70 minutes, but also significantly reduces plastic waste generated during the process. The kit aims to support more sustainable laboratory practices in drug development research.

Key Market Players

• Catalent, Inc.
• Quest Diagnostics Incorporated
• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• PerkinElmer, Inc.
• Thermo Fisher Scientific, Inc.
• Promega Corporation
• Luminex Corporation
• Takara Bio USA, Inc.
• Danaher Corporation

Report Scope:

In this report, the Global Gene Expression Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Gene Expression Market, By Process:

o   Sample Collection

o   Purification

o   cDNA synthesis & conversion

o   PCR Analysis

o   Data analysis & interpretation

• Gene Expression Market, By Product:

o   Kits & Reagents

o   DNA Chips

o   Others

• Gene Expression Market, By Capacity:

o   Low- to Mid- Plex

o   High-Plex

• Gene Expression Market, By Application:

o   Drug Discovery & Development

o   Clinical Diagnostics

o   Biotech & Microbiology

o   Others

• Gene Expression Market, By Technique:

o   RNA Expression

o   Promoter Analysis

o   Protein Expression& Posttranslational Modification Analysis

• Gene Expression Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Gene Expression Market.

Available Customizations:

Global Gene Expression Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Gene Expression Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]